Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript
Operator: Welcome to the Fate Therapeutics First Quarter 2024 Financial Results Conference Call [Operator Instructions].
Fate Therapeutics Inc (FATE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Redmile Group Jeremy Green | 13,169,057 | $46,091,700 | 2.71% | |
| 2. | Deep Track Capital David Kroin | 5,572,607 | $19,504,125 | 0.61% | |
| 3. | Citadel Investment Group Ken Griffin | 4,282,077 | $14,987,270 | -5% | 0% |
| 4. | Deerfield Management James E. Flynn | 3,555,871 | $12,445,549 | 0.18% | |
| 5. | D E Shaw D. E. Shaw | 3,377,650 | $11,821,776 | -18% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.72 | 44,630 | Large Shareholder, Director | 13,180,388 | 2023-12-26 | Filing | |
| $6.18 | 256,639 | Large Shareholder, Director | 13,135,758 | 2023-04-21 | Filing | |
| $5.99 | 20,000 | Large Shareholder, Director | 12,879,119 | 2023-04-20 | Filing | |
| $6.00 | 25,700 | Large Shareholder, Director | 12,859,119 | 2023-04-14 | Filing | |
| $5.43 | 36,631 | Director | 282,770 | 2023-01-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.23 | 633 | 8,669 | 2024-08-06 | Filing | ||
| $7.77 | 2,447 | 101,479 | 2024-03-04 | Filing | ||
| $5.00 | 1,849 | 103,926 | 2024-01-29 | Filing | ||
| $4.37 | 10,874 | 142,361 | 2024-01-09 | Filing | ||
| $4.38 | 11,271 | 158,069 | 2024-01-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,212,816 | $41,935,933 | 0% | |
| 2. | 9,293,363 | $34,757,178 | 0% | |
| 3. | 4,851,579 | $18,144,905 | 0.27% | |
| 4. | 3,379,064 | $12,637,699 | 0.28% | |
| 5. | 2,616,820 | $9,786,907 | 0.04% |
News See All
Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript
Fate Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.57. Fate Therapeutics, Inc.
13 Best Booming Stocks to Buy Right Now
Despite latest data showing elevated inflation and a decline in retail sales, some major investment firms are looking beyond the short-term market turbulence and issuing highly positive outlook for the...
5 Most Promising Cancer Stocks According to Analysts
In this piece, we will take a look at the five most promising cancer stocks according to analysts.
Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2023 Earnings Call Transcript
Operator: Welcome to the Fate Therapeutics Third Quarter 2023 Financial Results Conference Call. At this time, all participants are mode.
16 Most Shorted Stocks Right Now
One of the most intriguing plays on the stock market is short selling. This is because it goes against conventional investment logic, which typically seeks to profit from an increase in share prices.
5 Best High Short Interest Stocks To Buy Now
n this piece, we will take a look at the five best high short interest stocks to buy now.
Fate Therapeutics, Inc. (NASDAQ:FATE) Q2 2023 Earnings Call Transcript
Operator: Welcome to the Fate Therapeutics Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode.
Cathie Wood is Selling These 12 Stocks in 2023
After a bruising 2022, Cathie Wood’s funds slowly started to recover this year, thanks to the broader rally in the stock market amid hopes that the Federal Reserve could pause its rate-hike spree which...
Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2023 Earnings Call Transcript
Operator: Welcome to the Fate Therapeutics First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.